EKF Diagnostics Exhibiting Cutting-Edge POC Technology at Hospitalar 2013

17 May 2013
Share
EKF Diagnostics, worldwide manufacturer of point-of-care (POC) diagnostic tools, will be exhibiting its innovative range of analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases at Hospitalar 2013, Sao Paulo, Brazil (21-24 May).

On display in Green Hall - L81 - Stand 14 will be the new Quo-Lab and Quo-Test glycated hemoglobin (HbA1c) analyzers for near-patient measurement and monitoring of diabetes. HbA1c monitoring is increasingly used in the detection and management of diabetes and both analyzers provide highly accurate, affordable and easy-to-use technology, which uses just 4 µL of venous or finger prick blood to deliver lab-accurate results within four minutes.

Small and lightweight, Quo-Lab is designed specifically to meet the needs of clinics and laboratories in emerging economies, where diabetes is an increasingly large public health issue, and is ideal for GP surgeries, diabetes clinics and laboratories.

Also on show will be EKF’s globally successful haemoglobin analyzer, Hemo Control (also sold as HemoPoint H2 in USA and Asia). This portable and robust analyzer delivers lab quality results within 25 seconds (CV of <2%) for both hemoglobin and haematocrit from one simple test and, new for 2013, includes pre-loaded data management software.

Hemo Control uses unique microcuvette technology – the NXT microcuvette. This enables precise and easy blood collection and significantly reduces the risk of air bubbles appearing in blood samples. By minimizing occurrences of air bubbles in a sample, the NXT microcuvette ensures less waste with subsequent cost reductions.

Commenting on the production of the 33,333rd Hemo Control analyzer, Julian Baines, Group CEO, EKF Diagnostics Holdings plc., said, “A decade on from its launch, Hemo Control is more popular than ever before, and sales of devices and microcuvettes continue to grow. Our success in winning large government orders in Mexico, Peru and Tanzania, as well as our increasing market share in the USA under the HemoPoint H2 brand, demonstrates the strength of the brand in a very competitive market.”

EKF’s Lactate Scout+ hand-held lactate analyzer, that requires just 0.5ul of capillary blood and returns results in 10 seconds, will also be showcased. Lactate has traditionally been used in sports medicine to monitor athlete performance, however, EKF are now working with a number of new partners who are developing applications in obstetrics using the Lactate Scout+ analyzer and strip sensor technology.

Throughout Hospitalar 2013, EKF experts will be available to offer practical advice about how EKF’s cutting-edge solutions are revolutionizing the use of diagnostics in point of care settings and improving patient outcomes.

Request Info


Company website

EKF Diagnostics
profile photo

Sarah Thomas
Editorial Assistant